Development Process

2025/06

The company's product "Sunitinib Malate Capsules" was approved for listing.

2025/03

The company's product "Imatinib Mesylate Tablets" was approved for listing.

2024/12

The company's product "Erlotinib Hydrochloride Tablets" was approved for listing.

2024/11

The company's product "lenalidomide" was approved for listing.

2024/09

The company changed its name to “Guangzhou Keruite Pharmaceutical Co., Ltd.

2023/06

Acquisition of a pharmaceutical manufacturing license

2022/01

The pharmaceutical production license obtained

2020/05

Pharmaceutical factory put into use

2018/01

Construction of pharmaceutical factory started

2017/07

Set up research and development center, supporting domestic and foreign advanced research and development and testing equipment

2013/06

Company incorporation

Address: No.80, Spring Equinox Road, Huangpu District, Guangzhou

Telephone:020-8328 9091

Adverse Drug Reaction/Event Feedback E-mail:pvreport@bio-current.com

WeChat

Business License

About Us